FRANCIS REYNOLDS Insider Trading $NVIV INVIVO THERAPEUTICS HOLDINGS CORP.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for FRANCIS REYNOLDS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of FRANCIS REYNOLDS. FRANCIS REYNOLDS is CEO, CFO in INVIVO THERAPEUTICS HOLDINGS CORP. ($NVIV).
FRANCIS REYNOLDS in INVIVO THERAPEUTICS HOLDINGS CORP.
Trading Symbol: NVIVIndustry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of FRANCIS REYNOLDS: CEO, CFO
Holdings: 12,603,020 shares
Current Value: $56,083,439
Latest Transaction: Aug 21 2013
$NVIV Market Capitalization: $139.34M
$NVIV Previous Close: $4.45
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of FRANCIS REYNOLDS in INVIVO THERAPEUTICS HOLDINGS CORP.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 21 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.19 | 12,000 | 50,280 | 12,603,020 | 12.6 M to 12.6 M (-0.10 %) |
Aug 21 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.10 | 12,000 | 49,200 | 12,615,020 | 12.6 M to 12.6 M (-0.10 %) |
Aug 21 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.08 | 12,000 | 48,960 | 12,627,020 | 12.6 M to 12.6 M (-0.09 %) |
Aug 16 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.17 | 12,000 | 50,040 | 12,639,020 | 12.7 M to 12.6 M (-0.09 %) |
Aug 16 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.30 | 12,000 | 51,600 | 12,651,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.27 | 12,000 | 51,240 | 12,663,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.34 | 12,000 | 52,080 | 12,675,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.41 | 12,000 | 52,920 | 12,687,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.31 | 12,000 | 51,720 | 12,699,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 09 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.52 | 12,000 | 54,240 | 12,711,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.53 | 12,000 | 54,360 | 12,723,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.18 | 12,000 | 50,160 | 12,735,020 | 12.7 M to 12.7 M (-0.09 %) |
Aug 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.66 | 12,000 | 55,920 | 12,747,020 | 12.8 M to 12.7 M (-0.09 %) |
Aug 02 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.48 | 12,000 | 53,760 | 12,759,020 | 12.8 M to 12.8 M (-0.09 %) |
Aug 02 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.66 | 12,000 | 55,920 | 12,771,020 | 12.8 M to 12.8 M (-0.09 %) |
Jul 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.12 | 12,000 | 61,440 | 12,783,020 | 12.8 M to 12.8 M (-0.09 %) |
Jul 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.09 | 12,000 | 61,080 | 12,795,020 | 12.8 M to 12.8 M (-0.09 %) |
Jul 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.14 | 12,000 | 61,680 | 12,807,020 | 12.8 M to 12.8 M (-0.09 %) |
Jul 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.43 | 12,000 | 65,160 | 12,819,020 | 12.8 M to 12.8 M (-0.09 %) |
Jul 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.66 | 12,000 | 67,920 | 12,831,020 | 12.8 M to 12.8 M (-0.09 %) |
Jul 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.68 | 12,000 | 68,160 | 12,843,020 | 12.9 M to 12.8 M (-0.09 %) |
Jul 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.83 | 12,000 | 69,960 | 12,855,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.36 | 12,000 | 64,320 | 12,867,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.18 | 12,000 | 62,160 | 12,879,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.28 | 12,000 | 63,360 | 12,891,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 5.12 | 12,000 | 61,440 | 12,903,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.95 | 12,000 | 59,400 | 12,915,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.57 | 12,000 | 54,840 | 12,927,020 | 12.9 M to 12.9 M (-0.09 %) |
Jul 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.28 | 12,000 | 51,360 | 12,939,020 | 13 M to 12.9 M (-0.09 %) |
Jul 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.97 | 12,000 | 47,640 | 12,951,020 | 13 M to 13 M (-0.09 %) |
Jul 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.94 | 12,000 | 47,280 | 12,963,020 | 13 M to 13 M (-0.09 %) |
Jul 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.01 | 12,000 | 48,120 | 12,975,020 | 13 M to 13 M (-0.09 %) |
Jul 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.00 | 12,000 | 48,000 | 12,987,020 | 13 M to 13 M (-0.09 %) |
Jul 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.01 | 12,000 | 48,120 | 12,999,020 | 13 M to 13 M (-0.09 %) |
Jul 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.10 | 12,000 | 49,200 | 13,011,020 | 13 M to 13 M (-0.09 %) |
Jul 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.14 | 12,000 | 49,680 | 13,023,020 | 13 M to 13 M (-0.09 %) |
Jun 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.16 | 12,000 | 49,920 | 13,035,020 | 13 M to 13 M (-0.09 %) |
Jun 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.27 | 12,000 | 51,240 | 13,047,020 | 13.1 M to 13 M (-0.09 %) |
Jun 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.10 | 12,000 | 49,200 | 13,059,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.79 | 12,000 | 45,480 | 13,071,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.73 | 12,000 | 44,760 | 13,083,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 21 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.76 | 12,000 | 45,120 | 13,095,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 21 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.80 | 12,000 | 45,600 | 13,107,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.79 | 12,000 | 45,480 | 13,119,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.82 | 12,000 | 45,840 | 13,131,020 | 13.1 M to 13.1 M (-0.09 %) |
Jun 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.07 | 12,000 | 48,840 | 13,143,020 | 13.2 M to 13.1 M (-0.09 %) |
Jun 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.88 | 12,000 | 46,560 | 13,155,020 | 13.2 M to 13.2 M (-0.09 %) |
Jun 14 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.79 | 12,000 | 45,480 | 13,167,020 | 13.2 M to 13.2 M (-0.09 %) |
Jun 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.14 | 4,250 | 17,595 | 13,179,020 | 13.2 M to 13.2 M (-0.03 %) |
Jun 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.36 | 4,250 | 18,530 | 13,183,270 | 13.2 M to 13.2 M (-0.03 %) |
Jun 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.51 | 4,250 | 19,168 | 13,187,520 | 13.2 M to 13.2 M (-0.03 %) |
Jun 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 4.12 | 4,250 | 17,510 | 13,191,770 | 13.2 M to 13.2 M (-0.03 %) |
Jun 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.91 | 4,250 | 16,618 | 13,196,020 | 13.2 M to 13.2 M (-0.03 %) |
Jun 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.89 | 4,250 | 16,533 | 13,200,270 | 13.2 M to 13.2 M (-0.03 %) |
Jun 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.85 | 4,250 | 16,363 | 13,204,520 | 13.2 M to 13.2 M (-0.03 %) |
Jun 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.51 | 4,250 | 14,918 | 13,208,770 | 13.2 M to 13.2 M (-0.03 %) |
May 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.30 | 4,250 | 14,025 | 13,213,020 | 13.2 M to 13.2 M (-0.03 %) |
May 31 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.33 | 4,250 | 14,153 | 13,217,270 | 13.2 M to 13.2 M (-0.03 %) |
May 29 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.14 | 4,250 | 13,345 | 13,221,520 | 13.2 M to 13.2 M (-0.03 %) |
May 29 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.11 | 4,250 | 13,218 | 13,225,770 | 13.2 M to 13.2 M (-0.03 %) |
May 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.00 | 4,250 | 12,750 | 13,230,020 | 13.2 M to 13.2 M (-0.03 %) |
May 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.89 | 4,250 | 12,283 | 13,234,270 | 13.2 M to 13.2 M (-0.03 %) |
May 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.88 | 4,250 | 12,240 | 13,238,520 | 13.2 M to 13.2 M (-0.03 %) |
May 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.87 | 4,250 | 12,198 | 13,242,770 | 13.2 M to 13.2 M (-0.03 %) |
May 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.88 | 4,250 | 12,240 | 13,247,020 | 13.3 M to 13.2 M (-0.03 %) |
May 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.87 | 4,250 | 12,198 | 13,251,270 | 13.3 M to 13.3 M (-0.03 %) |
May 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.86 | 4,250 | 12,155 | 13,255,520 | 13.3 M to 13.3 M (-0.03 %) |
May 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.84 | 4,250 | 12,070 | 13,259,770 | 13.3 M to 13.3 M (-0.03 %) |
May 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.88 | 4,250 | 12,240 | 13,264,020 | 13.3 M to 13.3 M (-0.03 %) |
May 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.94 | 4,250 | 12,495 | 13,268,270 | 13.3 M to 13.3 M (-0.03 %) |
May 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.88 | 4,250 | 12,240 | 13,281,020 | 13.3 M to 13.3 M (-0.03 %) |
May 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.90 | 4,250 | 12,325 | 13,285,270 | 13.3 M to 13.3 M (-0.03 %) |
May 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.00 | 4,250 | 12,750 | 13,289,520 | 13.3 M to 13.3 M (-0.03 %) |
May 08 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Gift | G | 0.00 | 78,540 | 0 | 13,293,770 | 13.4 M to 13.3 M (-0.59 %) |
May 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.90 | 4,250 | 12,325 | 13,272,520 | 13.3 M to 13.3 M (-0.03 %) |
May 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.94 | 4,250 | 12,495 | 13,276,770 | 13.3 M to 13.3 M (-0.03 %) |
May 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.01 | 4,250 | 12,793 | 13,372,310 | 13.4 M to 13.4 M (-0.03 %) |
May 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.06 | 4,250 | 13,005 | 13,376,560 | 13.4 M to 13.4 M (-0.03 %) |
May 01 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.09 | 4,250 | 13,133 | 13,380,810 | 13.4 M to 13.4 M (-0.03 %) |
May 01 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.19 | 4,250 | 13,558 | 13,385,060 | 13.4 M to 13.4 M (-0.03 %) |
May 01 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.99 | 4,250 | 12,708 | 13,389,310 | 13.4 M to 13.4 M (-0.03 %) |
Apr 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.84 | 4,250 | 12,070 | 13,393,560 | 13.4 M to 13.4 M (-0.03 %) |
Apr 26 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.88 | 4,250 | 12,240 | 13,397,810 | 13.4 M to 13.4 M (-0.03 %) |
Apr 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.95 | 4,250 | 12,538 | 13,402,060 | 13.4 M to 13.4 M (-0.03 %) |
Apr 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.98 | 4,250 | 12,665 | 13,406,310 | 13.4 M to 13.4 M (-0.03 %) |
Apr 24 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.12 | 4,250 | 13,260 | 13,410,560 | 13.4 M to 13.4 M (-0.03 %) |
Apr 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.14 | 4,250 | 13,345 | 13,414,810 | 13.4 M to 13.4 M (-0.03 %) |
Apr 19 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.15 | 4,250 | 13,388 | 13,419,060 | 13.4 M to 13.4 M (-0.03 %) |
Apr 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.27 | 4,250 | 13,898 | 13,423,310 | 13.4 M to 13.4 M (-0.03 %) |
Apr 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.18 | 4,250 | 13,515 | 13,427,560 | 13.4 M to 13.4 M (-0.03 %) |
Apr 17 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.27 | 4,250 | 13,898 | 13,431,810 | 13.4 M to 13.4 M (-0.03 %) |
Apr 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.20 | 4,250 | 13,600 | 13,436,060 | 13.4 M to 13.4 M (-0.03 %) |
Apr 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.12 | 4,250 | 13,260 | 13,440,310 | 13.4 M to 13.4 M (-0.03 %) |
Apr 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.03 | 4,250 | 12,878 | 13,444,560 | 13.4 M to 13.4 M (-0.03 %) |
Apr 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 3.12 | 4,250 | 13,260 | 13,448,810 | 13.5 M to 13.4 M (-0.03 %) |
Apr 10 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.93 | 4,250 | 12,453 | 13,453,060 | 13.5 M to 13.5 M (-0.03 %) |
Apr 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.82 | 4,250 | 11,985 | 13,457,310 | 13.5 M to 13.5 M (-0.03 %) |
Apr 05 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.71 | 4,250 | 11,518 | 13,461,560 | 13.5 M to 13.5 M (-0.03 %) |
Apr 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.28 | 4,250 | 9,690 | 13,465,810 | 13.5 M to 13.5 M (-0.03 %) |
Apr 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.27 | 4,250 | 9,648 | 13,470,060 | 13.5 M to 13.5 M (-0.03 %) |
Apr 03 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.27 | 4,250 | 9,648 | 13,474,310 | 13.5 M to 13.5 M (-0.03 %) |
Mar 28 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.40 | 4,250 | 10,200 | 13,478,560 | 13.5 M to 13.5 M (-0.03 %) |
Mar 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.46 | 4,250 | 10,455 | 13,482,810 | 13.5 M to 13.5 M (-0.03 %) |
Mar 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.44 | 4,250 | 10,370 | 13,487,060 | 13.5 M to 13.5 M (-0.03 %) |
Mar 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.44 | 4,250 | 10,370 | 13,491,310 | 13.5 M to 13.5 M (-0.03 %) |
Mar 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.48 | 4,250 | 10,540 | 13,495,560 | 13.5 M to 13.5 M (-0.03 %) |
Mar 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.44 | 4,250 | 10,370 | 13,499,810 | 13.5 M to 13.5 M (-0.03 %) |
Mar 20 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.40 | 4,250 | 10,200 | 13,504,060 | 13.5 M to 13.5 M (-0.03 %) |
Mar 20 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.38 | 4,250 | 10,115 | 13,508,310 | 13.5 M to 13.5 M (-0.03 %) |
Mar 20 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.40 | 4,250 | 10,200 | 13,512,560 | 13.5 M to 13.5 M (-0.03 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.46 | 2,000 | 4,920 | 13,516,810 | 13.5 M to 13.5 M (-0.01 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.45 | 1,000 | 2,450 | 13,518,810 | 13.5 M to 13.5 M (-0.01 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.44 | 1,250 | 3,050 | 13,519,810 | 13.5 M to 13.5 M (-0.01 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.26 | 4,250 | 9,605 | 13,521,060 | 13.5 M to 13.5 M (-0.03 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.25 | 500 | 1,125 | 13,525,310 | 13.5 M to 13.5 M (0.00 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.22 | 2,500 | 5,550 | 13,525,810 | 13.5 M to 13.5 M (-0.02 %) |
Mar 15 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.20 | 1,250 | 2,750 | 13,528,310 | 13.5 M to 13.5 M (-0.01 %) |
Mar 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.22 | 1,200 | 2,664 | 13,529,560 | 13.5 M to 13.5 M (-0.01 %) |
Mar 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.21 | 2,100 | 4,641 | 13,530,760 | 13.5 M to 13.5 M (-0.02 %) |
Mar 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.20 | 950 | 2,090 | 13,532,860 | 13.5 M to 13.5 M (-0.01 %) |
Mar 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.14 | 4,250 | 9,095 | 13,533,810 | 13.5 M to 13.5 M (-0.03 %) |
Mar 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.26 | 300 | 678 | 13,538,060 | 13.5 M to 13.5 M (0.00 %) |
Mar 12 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.15 | 3,950 | 8,493 | 13,538,360 | 13.5 M to 13.5 M (-0.03 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.30 | 4,250 | 9,775 | 13,542,310 | 13.5 M to 13.5 M (-0.03 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.25 | 1,000 | 2,250 | 13,546,560 | 13.5 M to 13.5 M (-0.01 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.21 | 1,000 | 2,210 | 13,547,560 | 13.5 M to 13.5 M (-0.01 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.20 | 2,250 | 4,950 | 13,548,560 | 13.6 M to 13.5 M (-0.02 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.34 | 1,000 | 2,340 | 13,550,810 | 13.6 M to 13.6 M (-0.01 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.31 | 1,000 | 2,310 | 13,551,810 | 13.6 M to 13.6 M (-0.01 %) |
Mar 07 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.30 | 2,250 | 5,175 | 13,552,810 | 13.6 M to 13.6 M (-0.02 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.18 | 4,250 | 9,265 | 13,555,060 | 13.6 M to 13.6 M (-0.03 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.13 | 2,250 | 4,793 | 13,559,310 | 13.6 M to 13.6 M (-0.02 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.08 | 1,000 | 2,080 | 13,561,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.07 | 1,000 | 2,070 | 13,562,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.03 | 1,000 | 2,030 | 13,563,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.02 | 1,000 | 2,020 | 13,564,560 | 13.6 M to 13.6 M (-0.01 %) |
Mar 04 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 2.01 | 2,250 | 4,523 | 13,565,560 | 13.6 M to 13.6 M (-0.02 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.88 | 1,250 | 2,350 | 13,567,810 | 13.6 M to 13.6 M (-0.01 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.85 | 3,000 | 5,550 | 13,569,060 | 13.6 M to 13.6 M (-0.02 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.81 | 1,000 | 1,810 | 13,572,060 | 13.6 M to 13.6 M (-0.01 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.80 | 3,250 | 5,850 | 13,573,060 | 13.6 M to 13.6 M (-0.02 %) |
Feb 27 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.71 | 4,250 | 7,268 | 13,576,310 | 13.6 M to 13.6 M (-0.03 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.69 | 1,000 | 1,690 | 13,580,560 | 13.6 M to 13.6 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.68 | 390 | 655 | 13,581,560 | 13.6 M to 13.6 M (0.00 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.65 | 660 | 1,089 | 13,581,950 | 13.6 M to 13.6 M (0.00 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.64 | 2,200 | 3,608 | 13,582,610 | 13.6 M to 13.6 M (-0.02 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Gift | G | 0.00 | 171,000 | 0 | 13,584,810 | 13.8 M to 13.6 M (-1.24 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.70 | 1,000 | 1,700 | 13,755,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.69 | 1,000 | 1,690 | 13,756,810 | 13.8 M to 13.8 M (-0.01 %) |
Feb 22 2013 | NVIV | INVIVO THERAPEUTIC ... | REYNOLDS FRANCIS | CEO, CFO | Sell | S | 1.68 | 1,000 | 1,680 | 13,757,810 | 13.8 M to 13.8 M (-0.01 %) |